Introduction {#Sec1}
============

Pancreatic metastases are rare, ranging from 2 to 5% of pancreatic malignancies \[[@CR1], [@CR2]\]. The most common primary malignancies that metastasize to the pancreas are renal, lung, breast, and colon cancer, with sarcoma and melanoma observed less commonly \[[@CR2]--[@CR4]\]. Metastatic melanoma has a poor prognosis; the median survival for patients with stage IV melanoma ranges from 8 to 18 months after diagnosis \[[@CR5]\]. Isolated pancreatic metastasis is a rare event that represents about less than 1% of metastatic melanomas \[[@CR6]\].

Pancreatic metastases can resemble primary pancreatic malignancies, such as ductal carcinoma or neuroendocrine tumors. Thus, it can be difficult to differentiate pancreatic metastases from primary tumors based only on imaging findings. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) plays an important role in confirming the diagnosis \[[@CR1]\]. There are only a few reports on surgically resected pancreatic metastasis of malignant melanoma diagnosed by EUS-FNA \[[@CR3], [@CR7], [@CR8]\]. Here, we present a unique case of malignant melanoma with isolated pancreatic metastasis diagnosed by EUS-FNA and was treated with distal pancreatectomy.

Case report {#Sec2}
===========

A 67-year-old woman, who had been healthy all her life, presented to the referring hospital with left upper quadrant abdominal pain. Her ultrasonogram and computed tomography (CT) showed a mass in the pancreas, and the patient was referred to our institution for further examination.

Enhanced CT revealed that the mass was localized to the tail of the pancreas, with pancreatic ductal dilatation. The mass was a rounded, well-defined lesion with low attenuation, surrounded by a high-attenuation rim (Fig. [1](#Fig1){ref-type="fig"}a). Magnetic resonance imaging (MRI) showed that the center of the mass was hyperintense on T1-weighted image and hypointense on T2-weighted image (Fig. [1](#Fig1){ref-type="fig"}b, c). The diffusion-weighted image showed a hyperintense peripheral rim of the mass (Fig. [1](#Fig1){ref-type="fig"}d). Endoscopic retrograde cholangiopancreatogram demonstrated smooth narrowing and displacement of the pancreatic duct with upstream dilatation (Fig. [2](#Fig2){ref-type="fig"}). EUS revealed the 35-mm mass to be hypoechoic and heterogeneous with central anechoic areas (Fig. [3](#Fig3){ref-type="fig"}a, b). Contrast-enhanced EUS (CE-EUS) was conducted using an electronic radial-type endoscope (GF-UE260; Olympus, Japan) and perflubutane as ultrasound contrast agent. CE-EUS showed isoenhancement during the 20-s phase (Fig. [3](#Fig3){ref-type="fig"}c) and hypoenhancement during the 120-s phase (Fig. [3](#Fig3){ref-type="fig"}d) of the peripheral rim of the mass with central non-enhancement.Fig. 1Computed tomography image. **a** Mass in the tail of the pancreas with pancreatic ductal dilation. The central mass is hyperintense on T1-weighted image (**b**) and hypointense on T2-weighted image (**c**). **d** Peripheral rim of the mass is hyperintense on diffusion-weighted imageFig. 2Endoscopic retrograde cholangiopancreatogram revealed smooth narrowing and displacement of the pancreatic duct with upstream dilatationFig. 3Endoscopic ultrasonography revealed hypoechoic and homogenous heterogeneous mass (**a**) with central anechoic areas (**b**, arrow). Contrast-enhanced endoscopic ultrasonography shows isoenhancement at 20 s (**c**) and hypoenhancement at 120 s (**d**) with central non-enhancement of the peripheral rim of the mass

Cytological analysis obtained by EUS-FNA with a 22-gauge needle (Fig. [4](#Fig4){ref-type="fig"}a) revealed a large nucleus and a high nuclear/cytoplasmic ratio in the cells, with brown pigmentation (Fig. [4](#Fig4){ref-type="fig"}b). The cells were positive for Melan A and Human Melanoma Black 45 (HMB-45) and were negative for S100 on cell-block immunocytochemical analysis (Fig. [4](#Fig4){ref-type="fig"}c, d). Thus, the patient was diagnosed as having malignant melanoma.Fig. 4**a** Endoscopic ultrasound-guided fine-needle aspiration of the peripheral rim of the mass. **b** Cytologic results revealed a large nucleus and a high nuclear/cytoplasmic ratio in the cells, with brown pigmentation. Immunocytochemical staining with Melan A (**c**) and Human Melanoma Black 45 (**d**)

Since primary pancreatic malignant melanoma has never been reported before, we suspected metastatic malignant melanoma of the pancreas. However, intense fluorodeoxyglucose uptake was observed only in the tail of the pancreas on positron emission tomography--CT (PET-CT) (Fig. [5](#Fig5){ref-type="fig"}). Esophagogastroduodenoscopy and colonoscopy did not reveal any specific findings. The primary site could not be identified by dermatological, ophthalmological, or gynecological examination.Fig. 5Intense fluorodeoxyglucose uptake only in the body and tail of the pancreas (arrow)

Distal pancreatectomy was performed. Histological examination of the surgical specimen revealed malignant melanoma with central necrosis (Figs. [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}). The resection specimen stained for Melan A and HMB-45, but not for S100. The patient underwent interferon-alfa treatment as an adjuvant therapy. Six months postoperatively, the follow-up PET-CT showed high uptake in the left nasal cavity, left infraclavicular lymph, and peritoneum (Fig. [8](#Fig8){ref-type="fig"}). On fiber-optic laryngoscopy, a whitish mass was detected in the left nasal cavity, which was determined to be a malignant melanoma. Although melanin was unclear in the nasal cavity biopsy specimen, cell shape and immunohistochemistry findings were the same as those in the resected surgical specimen. The primary site of the malignant melanoma was the left nasal cavity, and the pancreatic mass, left infraclavicular lymph, and peritoneal lesion were metastases. Nivolumab was started; thereafter, the treatment was switched to pembrolizumab. The patient had survived for more than 2 years after the distal pancreatectomy.Fig. 6Resected surgical specimen showing a black--brown mass in the tail of the pancreasFig. 7**a** Loupe image of the resection specimen. The peripheral rim of the mass has nodular components (arrows). **b** Tumor cells in the peripheral rim of the mass have anisokaryosis and clear nuclei with melanin production. **c** Center of the mass was necroticFig. 8Positron emission tomography--computed tomography image of the nasal cavity before (**a**) and after surgery (**b**). Plane computed tomography and positron emission tomography--computed tomography images after surgery revealed left infraclavicular lymph node metastasis (**c**, **d**) and a small peritoneal nodule (**e**, **f**)

Discussion {#Sec3}
==========

Malignant melanoma usually metastasizes to the gastrointestinal tract, and metastatic malignant melanoma usually affects multiple sites. Isolated organ metastasis is unusual; specifically, metastasis to the pancreas is extremely rare (\< 1%) \[[@CR6]\]. There are 76 cases of pancreatic metastasis from malignant melanoma reported in English (Table [1](#Tab1){ref-type="table"}). The major primary site is cutaneous and ocular. Meanwhile, there are only three cases of pancreatic metastasis from nasal cavity malignant melanoma, including our case \[[@CR9], [@CR10]\]. Sometimes, the primary lesion of melanoma is difficult to identify during pretreatment evaluation. In our case, the primary site was identified by PET-CT 6 months postoperatively, even though PET-CT is only effective for detecting primary tumors or cancers of unknown primary.Table 1Metastatic malignant melanoma of pancreas reported in the English literatureAuthorsYear of publicationAgeSexCasePrimary siteLocation in the pancreasTumor size (cm)Diagnostic modalitySurgeryFollow-up (month)OutcomeDas Gupta et al. \[[@CR21]\]196444Female2CutaneousBody and tailNRExploratory laparotomyNo operation2Dead28MaleCutaneousBody and tailNRExploratory laparotomyDP10DeadJohansson et al. \[[@CR22]\]197067Female1OcularHeadNRBiopsyPD11AliveBianca et al. \[[@CR23]\]199148Male1UnknownHead3FNAPD12AliveBrodish et al. \[[@CR24]\]199375Female1CutaneousTail5CTDP12AliveRütter et al. \[[@CR9]\]199455Male1Unknown (1 year after surgery, melanoma detected in nasal cavity and nasopharynx)Head2.5ERCPDP12AliveSobesky et al. \[[@CR25]\]199732Female1Thoracic melanomaDiffuse infiltrationNRERCP, biopsyNo operation1.5DeadHarrison et al. \[[@CR26]\]1997NRNR1NRNRNRNRNRNRNRMedina-Franco et al. \[[@CR27]\]199960Male1UnknownHead8CT, USPD6DeadWood et al. \[[@CR19]\]2001NRNR8NRNRNRNRCurative resection or palliative resectionMedian 23.8NRNR20NRNRNRNRno operationMedian 15.2Hiotis et al. \[[@CR28]\]2002NRNR1NRNRNRNKPDNRDeadCamp et al. \[[@CR29]\]200262Female1OcularBody5CT, PET-CTDP20AliveDewitt et al. \[[@CR30]\]200333Male2UnknownHead5EUS-FNAPalliative gastrojejunostomy6Dead83FemaleUnknownTail3EUS-FNANo operation10AliveMizushima et al. \[[@CR31]\]200351Female1CutaneousHead5BiopsyNo operationNRNRNikfarjam et al. \[[@CR32]\]200345Male2OcularHead3CT, MRI, PET-CT etc.PD6Alive55MaleOcularHead, body, tailNRCT, PET-CT etc.TP7AliveCarboni et al. \[[@CR33]\]200455Female1CutaneousHead8BiopsyPD4DeadCrippa et al. \[[@CR34]\]200636Female1NRHeadNRNRPD14DeadBelágyi et al. \[[@CR35]\]200628Female1OcularBodyNRCTPancreatic enucleation etc.4DeadEidt et al. \[[@CR36]\]2007NRNR4NRNR8NRPD76AliveNRNRNRNR5NRPD30AliveNRNRNRNR7NRPD12DeadNRNRNRNR5NRPD25DeadReddy et al. \[[@CR37]\]2008NRNR3NRNRMedian size 4NRNRMedian 10.8Dumitraşcu et al. \[[@CR7]\]200843Female1OcularBody2EUS-FNACP12AliveLanitis et al. \[[@CR38]\]201069Male1CutaneousHead4.5CTPD96AliveHe et al. \[[@CR39]\]201039Male1OcularTail18CT, MRI, ERCP etc.DP25AliveVagefi et al. \[[@CR8]\]201057Female1OcularTail2.2EUS-FNADPNRNRPortale et al. \[[@CR4]\]201143Female1UnknownTail1.7US, CT, PET-CTDPNRNRMoszkowicz et al. \[[@CR40]\]201144Female1CutaneousUncinate process, Cephalo-isthmic junction1.3, 0.9Biopsy under EUSPDNRNRSperti et al. \[[@CR41]\]201148Male1UnknownBody2.9CTDP24DeadGoyal et al. \[[@CR18]\]201247Female5CutaneousHead3ERCP-assisted biopsyPD15Dead73FemaleCutaneousHead4CTPD3Dead58FemaleUnknownHead10CT-guided biopsyPD11.4Dead28FemaleCutaneousHead2PET-CTPD4.5Dead69MaleUnknownTail4.5BiopsyDP26DeadLarsen et al. \[[@CR2]\]201332Female1CutaneousHeadNRCTPD228AliveBirnbaum et al. \[[@CR5]\]201345Female1CutaneousHead6BiopsyPD19AliveSugimoto et al. \[[@CR10]\]201346Male1Nasal cavityBody3.3CT, PET-CTDP10DeadSolmaz et al. \[[@CR42]\]201459Male1CutaneousHead3.8BiopsyNo operationNRNRJana et al. \[[@CR1]\]201575Male1CutaneousHead, body2.4, 1.4, 1, 0.6EUS-FNANo operationNRNRDe Moura et al. \[[@CR3]\]201658Female1OcularHead, neck3.1EUS-FNAPDNRNRNadal et al. \[[@CR43]\]201657Female1OcularTail2EUS-FNANRNRNRBen Slama et al. \[[@CR44]\]201755Female1UnknownHead5.5CT, MRIPD15AliveLiu et al. \[[@CR45]\]201854Male1CutaneousHead3.1CTPD6AliveCurrent201967Female1Nasal cavityBody3.5EUS-FNADP24Alive*NR* not reported, *PD* pancreatoduodenectomy, *DP* distal pancreatectomy, *TP* total pancreatectomy, *CP* central pancreatectomy

Despite technological advances, preoperative diagnosis of metastatic pancreatic tumor is sometimes difficult \[[@CR11]\]. Metastatic lesions from malignant melanoma have hypervascularity on contrast-enhanced CT and MRI \[[@CR12]\]. The blood supply to metastatic lesions is carried from the surrounding organs; therefore, the surrounding tissue of the large lesion receives more blood supply than the central area, resulting in rim enhancement, especially in lesions larger than 1.5 cm. The same could be said in our case, as a high-attenuation rim was revealed on enhanced CT. EUS provided us with high-quality images to examine the pancreas and nearby structures. In general, pancreatic metastases on EUS have regular margins and appear as homogenous structures that are hypoechoic compared with the surrounding pancreas \[[@CR13]\]. In our case, EUS revealed the mass to be hypoechoic and homogenous with the central anechoic areas. Few studies have reported on CE-EUS findings of pancreatic metastatic lesion. Pancreatic metastasis of renal cell carcinoma tends to show hyperenhancement, whereas malignant melanoma may or may not show hyperenhancement \[[@CR13]--[@CR15]\]. The lack of characteristic findings makes diagnosis of metastatic malignant melanoma by CE-EUS difficult.

To confirm the diagnosis of pancreatic metastatic lesions, pathological examination is necessary. EUS-FNA plays an important role in providing cytological/histological diagnosis, and it is extremely useful in identifying pancreatic metastases. To distinguish pancreatic metastases from a primary carcinoma accurately, effective sampling and immunocytochemistry are needed \[[@CR1], [@CR3], [@CR6]\]. EUS-FNA with rapid on-site evaluation provides effective sampling, because a cytopathologist can ensure that the samples are adequate for assessment \[[@CR16]\]. Immunohistochemical analysis has been shown to be useful in identifying metastatic melanoma; the sensitivity of S100, Melan A, and HMB-45 are reported to be 97--100%, 75--92%, and 69--93%, respectively. The specificity of S100 and Melan A is reported to be 75--87% and 95--100%, respectively \[[@CR17]\]. In our case, Melan A and HMB-45 were positive.

The prognosis of patients with malignant melanoma metastatic to the pancreas is unknown, although metastatic melanoma usually indicates poor prognosis \[[@CR5]\]. There are few experiences with pancreatic resection for isolated pancreatic metastases, and pancreatic resection is controversial. Some studies have shown that complete surgical resection of a localized metastatic disease can prolong survival \[[@CR5], [@CR18]\]. However, Wood et al. \[[@CR19]\] reported 28 patients with isolated pancreatic metastases from malignant melanoma and found that the 5-year survival rate of pancreatic resection (performed in 8 patients) was 37.5% (median survival, 23.8 months), as compared with 23% (median survival, 15.2 months) of the 20 patients treated with non-resection. It is critical that surgery should be performed only when a complete resection is possible. Therefore, exhaustive preoperative staging is needed to confirm both the absence of local invasion of the major vasculature and the absence of distant metastasis. PET scan has a high sensitivity and specificity for detecting metastasis from malignant melanoma \[[@CR20]\]. In our case, PET-CT also had an important role; preoperative PET-CT identified the pancreatic tail mass, and the 6-month postoperative PET-CT showed high uptake in the left nasal cavity and peritoneum.

In conclusion, this unique case of isolated pancreatic metastasis from malignant melanoma was conclusively proven with EUS-FNA prior to the diagnosis of the primary lesion. Broad differential diagnoses should be considered when faced with inconclusive imaging studies of pancreatic tumors. In such cases, EUS-FNA is useful in providing a definitive diagnosis.
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